Sign in to continue:

Tuesday, March 10th, 2026

China Taiping Insurance Holdings Announces Board Meeting on March 25, 2026 to Approve 2025 Annual Results and Dividend 1

China Taiping Insurance Holdings Announces Board Meeting Date for Annual Results and Dividend Consideration

China Taiping Insurance Holdings Schedules Board Meeting to Consider 2025 Annual Results and Final Dividend

China Taiping Insurance Holdings Company Limited (Stock Code: 966), a major Hong Kong-listed insurance group, has announced that it will hold a crucial board meeting on Wednesday, 25 March 2026. This meeting is set to discuss and approve several key matters that are highly relevant to shareholders and potential investors.

Key Points of the Announcement

  • Date of Meeting: The board of directors will meet on 25 March 2026.
  • Main Agenda: The meeting will focus on:
    • Considering and approving the audited annual results for the financial year ended 31 December 2025.
    • Determining the payment of a final dividend for shareholders, if any.
  • Disclosure: The announcement was issued on 9 March 2026 by Ms. Zhang Ruohan, Company Secretary.
  • Board Composition: As of the announcement date, the board comprises 10 directors, including executive, non-executive, and independent non-executive directors.

Important Information for Shareholders

  • Potential Price Sensitivity: The results of the upcoming board meeting could have a significant impact on China Taiping’s share price. The approval and release of annual results typically provide insights into the company’s financial health, profitability, and business outlook. Strong or weak results could influence investor sentiment and market valuation.
  • Dividend Declaration: Perhaps most crucial for existing and prospective shareholders, the board will consider the payment of a final dividend. The size and existence of the dividend is often viewed as a reflection of management’s confidence in current and future earnings, and can directly affect the attractiveness of the stock to income-seeking investors.
  • Regulatory Compliance: The announcement follows standard listing regulations on the Hong Kong Stock Exchange, ensuring transparency and timely communication with the market.

What Investors Should Watch

  • The Release of 2025 Annual Results: Investors are advised to closely monitor the publication of the audited annual results. These figures will provide a comprehensive picture of the company’s performance in 2025, including revenue, profit, and any strategic developments.
  • Dividend Decision: Any announcement regarding the final dividend, including its amount and payment date, could have a direct impact on share price and should be assessed in the context of the company’s payout history and sector peers.
  • Board’s Outlook and Guidance: Shareholders should pay attention to any comments or guidance provided by the board following the meeting, as these may signal management’s expectations for 2026 and beyond.

Board of Directors

As of 9 March 2026, the board consists of:

  • Executive Directors: Mr. Yin Zhaojun, Mr. Li Kedong, Ms. Na Yanfang
  • Non-Executive Directors: Mr. Hu Xingguo, Mr. Zhou Lianggang, Mr. Feng Zhanwu
  • Independent Non-Executive Directors: Mrs. Law Fan Chiu Fun Fanny, Ms. Liu Yi, Mr. Shiu Sin Por, Mr. Cai Hongping

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisers before making any investment decisions. The company’s results and dividend decisions are subject to approval by the board and may differ from market expectations.


View CHINA TAIPING Historical chart here



Fantasia Holdings Group Co., Limited Announces Extraordinary General Meeting for Approval of Restructuring Agreement (March 2026)

Fantasia Holdings Group Co., Limited: Notice of Extraordinary General Meeting and Major Restructuring Fantasia Holdings Group Co., Limited Announces Extraordinary General Meeting to Approve Major Restructuring Key Points Investors Must Note Date and Venue...

Beijing Enterprises Water Group Board Meeting Scheduled for Final Results and Dividend Announcement on March 25, 2026 1

Beijing Enterprises Water Group Limited Announces Upcoming Board Meeting to Approve 2025 Final Results Beijing Enterprises Water Group Limited Schedules Board Meeting to Approve 2025 Final Results and Consider Final Dividend Key Highlights for...

Sino Biopharm’s Rovadicitinib Tablet Approved in China as First-Line Treatment for Myelofibrosis, Shows Superior Efficacy and Safety 12

Sino Biopharmaceutical’s Rovadicitinib Tablet Approved for Marketing in China: Key Details for Investors Sino Biopharmaceutical’s Rovadicitinib Tablet Receives Landmark Approval in China Key Highlights and Investor-Relevant Insights First-in-Class Approval: Sino Biopharmaceutical Limited (HKEX: 1177)...

   Ad